Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Voss, Ulrikke ^a   Sand, Elin ^a   Hellström, Per M ^b   Ekblad, Eva ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN[9-39]AMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; NEUROTENSIN 6 11; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE 7 28; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; (VIP NEUROTENSIN) HYBRID ANTAGONIST; (VIP-NEUROTENSIN) HYBRID ANTAGONIST; EXENDIN (9 39) AMIDE; EXENDIN (9-39) AMIDE; HYBRID PROTEIN; NEUROPROTECTIVE AGENT; NEUROTENSIN; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; MAST CELL; MYENTERIC PLEXUS; NERVE CELL; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PERITONEUM MAST CELL; PROTEIN FUNCTION; RAT; SMALL INTESTINE; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; DRUG EFFECT; INNERVATION; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; INTESTINE, SMALL; MAST CELLS; MYENTERIC PLEXUS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTENSIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84859042269     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-30     Document Type: Article

References (46)

1. Hammar J, Howell S, Bytzer P, Horowitz M, Talley NJ. Symptom clustering in subjects with and without diabetes mellitus: A population-based study of 15 000 Australian adults. Am J Gastroenterol 2003, 98:391-398.
2. Chandrasekharan B, Srinivasan S. Diabetes and the enteric nervous system. Neurogastroenterol Motil 2007, 19:951-960.
3. Guo C, Quobatari A, Shangguan Y, Hong S, Wiley JW. Diabetic autonomic neuropathy: evidence for apoptosis in situ in the rat. Neurogastroenterol Motil 2004, 16:335-345. 10.1111/j.1365-2982.2004.00524.x, 15198656.
4. Shotton HR, Broadbent S, Lincoln J. Prevention and partial reversal of diabetes-induced changes in enteric nerves of rat ileum by combined treatment with alpha-lipoic acid and evening primrose oil. Autonom Neurosci 2004, 111:57-65.
5. Voukali E, Shotton HR, Lincoln J. Selective responses of myenteric neurons to oxidative stress and disbetic stimuli. Neurogastroenterol Motil 2011, 23:964-e411. 10.1111/j.1365-2982.2011.01778.x, 21914042.
6. Brubaker PL. Minireview: Update on incretin biology: Focus on glucagon-like peptide-1. Endocrinology 2010, 151:1984-1989. 10.1210/en.2010-0115, 20305008.
7. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278:471-478.
8. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009, 106:1285-1290. 10.1073/pnas.0806720106, 2633544, 19164583.
9. Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Brit J Pharmacol 2010, 159:495-501.
10. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res 2009, 40:536-544. 10.1016/j.arcmed.2009.09.005, 20082866.
11. Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 2007, 203:293-301. 10.1016/j.expneurol.2006.09.028, 1850958, 17125767.
12. Hellström PM, Hein J, Björnsson E, Kristensen J, Schambye H. Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther 2008, 29:198-206.
13. Estall JL, Drucker DJ. Glucagon-like peptide 2. Ann Rev Nutr 2006, 26:391-411.
14. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of glucagons-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007, 293:G211-221. 10.1152/ajpgi.00530.2006, 17395898.
15. Sigalet DL, Wallace L, De Heuval E, Sharkey KA. The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastrenterol Motil 2010, 22:1318-1325.
16. Arciszewski MB, Ekblad E. Effects of vasoactive intestinal peptide and galanin on survival of cultured porcine myenteric neurons. Regulatory Peptides 2005, 125:185-192. 10.1016/j.regpep.2004.08.036, 15582731.
17. Arciszewski MB, Sand E, Ekblad E. Vasoactive intestinal peptide rescues cultured rat myenteric neurons from lipopolysaccharide induced cell death. Regulatory Peptides 2008, 146:218-223. 10.1016/j.regpep.2007.09.021, 17919746.
18. Brenneman DE. Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Peptides 2007, 28:1720-1726. 10.1016/j.peptides.2007.04.002, 17513014.
19. Sandgren K, Lin Z, Ekblad E. Differential effects of VIP and PACAP on survival of cultured adult rat myenteric neurons. Regulatory Peptides 2003, 111:211-217. 10.1016/S0167-0115(02)00290-2, 12609771.
20. Sandgren K, Lin Z, Fex-Svenningsen T, Ekblad E. Vasoactive intestinal peptide and nitric oxide promote survival of adult rat myenteric neurones in culture. J Neurosci Res 2003, 72:595-602. 10.1002/jnr.10612, 12749024.
21. Sand E, Themner-Persson A, Ekblad E. Mast cells reduce survival of myenteric neurons in culture. Neuropharmacol 2009, 56:522-530.
22. Lin Z, Sandgren K, Ekblad E. Increased expression of vasoactive intestinal peptide in cultured myenteric neurons from rat small intestine. Autonom Neurosci 2003, 107:9-19.
23. Sand E, Themner-Persson A, Ekblad E. Corticotropin releasing factor - Distribution in rat intestine and role in neuroprotection. Regulatory Peptides 2011, 166:68-75. 10.1016/j.regpep.2010.08.011, 20801165.
24. Håkanson R, Böttcher G, Ekblad E, Panula P, Simonsson M, Dohlsten M, Hallberg T, Sundler F. Histamine in endocrine cells in the stomach: a survey of several species using a panel of histamine antibodies. Histochemistry 1986, 86:5-17. 10.1007/BF00492340, 2878908.
25. Ørskov C, Holst JJ. Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 1987, 47:165-74. 10.3109/00365518709168885, 3576119.
26. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptides-1 in the rat. Neurogastroenterol Motil 2009, 21:978-e78. 10.1111/j.1365-2982.2009.01317.x, 19453518.
27. Fischer KD, Dhanvantari S, Drucker DJ, Brubaker PL. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. Am J Physiol 1997, 273:E815-820.
28. Matsumura M, Saito S. Effect of bile salts on the plasma concentration of immunoreactive vasoactive intestinal polypeptide in man. Endocrinol Jpn 1989, 36:15-21. 10.1507/endocrj1954.36.15, 2731483.
29. Shimatsu A, Kato Y, Matsushita N, Katakami H, Yanaihara N, Imura H. Stimulation by serotonin of vasoactive intestinal polypeptide release into rat hypophysial portal blood. Endocrinology 1982, 111:338-340. 10.1210/endo-111-1-338, 7084118.
30. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisenga JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 1998, 50:265-270.
31. Moody TW, Jensen RT, Fridkin M, Gozes I. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci 2002, 17:29-35.
32. Martin JH, Deacon CF, Gorell MD, Prins JB. Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 2011, 41:299-307. 10.1111/j.1445-5994.2011.02439.x, 21299778.
33. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagons-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002, 302:881-888. 10.1124/jpet.102.037481, 12183643.
34. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 2003, 9:1173-1179. 10.1038/nm919, 12925848.
35. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157. 10.1053/j.gastro.2007.03.054, 17498508.
36. Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi M, Mulè F. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil 2010, 22:664-671. 10.1111/j.1365-2982.2010.01476.x, 20158614.
37. Kirchgessner AL, Liu MT, Gershon MD. In situ identification and visualization of neurons that mediate enteric and enteropancreatic reflexes. J Comp Neurol 1996, 371:270-286. 10.1002/(SICI)1096-9861(19960722)371:2<270::AID-CNE7>3.0.CO;2-#, 8835732.
38. Sörhede Winzell M, Ahrén B. G-protein-coupled receptors and islet function - Implications for treatment of type 2 diabetes. Pharmacol Ther 2007, 116:437-448. 10.1016/j.pharmthera.2007.08.002, 17900700.
39. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D, Nichols BL, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006, 130:150-164. 10.1053/j.gastro.2005.11.005, 16401478.
40. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrintest Liver Physiol 2011, 301:G1-8.
41. Amato A, Baldassano S, Serio R, Mulè F. Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrintest Liver Physiol 2009, 296:G678-684.
42. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004, 145:3495-3506. 10.1210/en.2004-0100, 15059959.
43. Shi X, Li X, Wang Y, Zhang K, Zhou F, Chan L, Li D, Guan X. Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway. Am J Physiol Endocrinol Metab 2011, 300:E554-563. 10.1152/ajpendo.00620.2010, 3279303, 21177288.
44. Zhang J, Shi G-P. Mast cells and metabolic syndrome. Biochem Biophys Acta 2012, 1822:14-20.
45. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 2007, 123:398-410. 2433325, 17922833.
46. Korkmaz OT, Tunçel N, Tunçel M, Öncü EM, Şahintürk V, Çelik M. Vasoactive intestinal peptide (VIP) treatment of parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci 2010, 41:278-287. 10.1007/s12031-009-9307-3, 19953344.